NEWSMORE TRAVEL GRANTS AVAILABLE
Twenty more travel grants available for RSV Vaccines for the World, Málaga. We highly encourage junior or mid-stage career researchers and scientists/physicians from low and middle income countries to attend RSVVW. If you want be considered for a travel grant, please send an email with your details (country, current title, university) and abstract to info@resvinet.org to subscribe. Selection will be based on the quality of abstracts and geographic location of the author. Online registration is not needed. Please be noted that the deadline is September 1st, 2017.
rsvvw - TRAVEL GRANTS availableWe are happy to inform you that we have travel grants for junior or mid-stage career researchers. EU awardees will receive 1000 Euro, non-EU awardees will receive 2000 Euro as a lump sum for all expenses. At least 20 travel grants will be available. Applicants are required to submit an abstract. If there are more applicants than available grants as of August 7, selection will be based on the quality of abstracts and geographic location of the author. After August 7, additional travel grants may be awarded based on availability of funds as well as abstract quality.
We highly encourage young researchers (specifically from low and middle income countries) to be part of RSV Vaccines for the World in November. If you want be considered for a travel grant, please send an email with your details (country, current title, university) and abstract to info@resvinet.org to subscribe. Online registration is not needed. RSVVW in Málaga - Registration open
We are pleased to announce that the on-line registration is now openend for the "RSV Vaccines For The World" conference to be held in Málaga, Spain on November 29th - December 1st, 2017.
Be PART OF THE 4th RSV Expert MeetingWe are delighted to announce 4th Annual ReSViNET Meeting "RSVVW" RSV Vaccines For The World". This yearly RSV expert meeting is devoted exclusively to RSV infection prevention and treatment and will take place in Málaga, Spain.
Please click here for more information about the meeting 
|
A highly potent extended half-life antibody as a potential RSV vaccine surrogate for all infants
Qing Zhu,1*† Jason S. McLellan,2† Nicole L. Kallewaard,1 Nancy D. Ulbrandt,1 Susan Palaszynski,1 Jing Zhang,1 Brian Moldt,1 Anis Khan,3 Catherine Svabek,1 Josephine M. McAuliffe,1 Daniel Wrapp,2 Nita K. Patel,1 Kimberly E. Cook,4 Bettina W. M. Richter,1 Patricia C. Ryan,5 Andy Q. Yuan,4 JoAnn A. Suzich1* ReSViNET sites
|
about REsvinet
RSV (Respiratory Syncytial Virus) infection is the second most important cause of death during infancy, especially in developing countries. RSV infection has also been linked to an increased risk in the development of chronic airway disease in later life. Therefore, research on RSV is crucial.
In order to improve research on RSV, ReSViNET (Respiratory Syncytial Virus Network) has been established. In this network, expertise and leadership are combined in order to decrease the global burden of RSV. It is our goal to improve knowledge of RSV epidemiology and to develop safe and effective therapeutic and preventive interventions.
In order to improve research on RSV, ReSViNET (Respiratory Syncytial Virus Network) has been established. In this network, expertise and leadership are combined in order to decrease the global burden of RSV. It is our goal to improve knowledge of RSV epidemiology and to develop safe and effective therapeutic and preventive interventions.
